A new study reveals that the COVID-19 vaccine developed by a major pharmaceutical company has shown promising early results in clinical trials, with participants demonstrating a strong immune response after receiving two doses. Researchers noted that the vaccine triggered both antibody and T-cell responses, which are critical for fighting the virus. While the findings are preliminary, they suggest potential effectiveness in preventing infection, though further testing is required before widespread distribution. The study highlights a key step forward in the global effort to combat the pandemic, though experts emphasize the need for continued caution.
